Aprea Therapeutics Inc.

3.64-0.0600-1.62%Vol 1.48K1Y Perf -61.02%
Dec 6th, 2023 13:29 DELAYED
BID3.64 ASK3.75
Open3.60 Previous Close3.70
Pre-Market- After-Market-
 - -  - -%
Target Price
3.00 
Analyst Rating
Strong Buy 1.00
Potential %
-17.58 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
100/33/-56 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
100/-2/-86 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
100/42/-36 
Income Ranking
 —    -
Price Range Ratio 52W %
9.33 
Earnings Rating
Market Cap13.60M 
Earnings Date
8th Nov 2023
Alpha0.33 Standard Deviation2.90
Beta2.20 

Today's Price Range

3.603.91

52W Range

2.7812.00

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
0.00%
1 Month
-11.44%
3 Months
-6.19%
6 Months
2.54%
1 Year
-61.02%
3 Years
-99.41%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
APRE3.64-0.0600-1.62
AAPL192.32-1.1000-0.57
GOOG131.43-0.9600-0.73
MSFT368.81-3.7150-1.00
XOM99.11-1.3300-1.32
WFC44.500.01000.02
JNJ156.62-1.9300-1.22
FB196.640.99000.51
GE119.81-0.4200-0.35
JPM156.31-1.6600-1.05
Financial StrengthValueIndustryS&P 500US Markets
8.30
8.40
0.00
0.00
-7 393.30
Leverage Ratio 3.60
ProfitabilityValueIndustryS&P 500US Markets
-
-
-
-
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-
-
Earnings HistoryEstimateReportedSurprise %
Q03 2023-1.08-0.8620.37
Q02 2023-1.43-0.8739.16
Q01 2023-1.51-1.3411.26
Q04 2022-2.60-0.9264.62
Q03 2022-5.60-2.4057.14
Q02 2022-7.60-19.80-160.53
Q01 2022-7.60-7.205.26
Q04 2021-8.80-7.2018.18
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-1.08
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume1.48K
Shares Outstanding3.74K
Shares Float2.96M
Trades Count26
Dollar Volume5.54K
Avg. Volume7.99K
Avg. Weekly Volume9.06K
Avg. Monthly Volume4.67K
Avg. Quarterly Volume10.22K

Aprea Therapeutics Inc. (NASDAQ: APRE) stock closed at 3.64 per share at the end of the most recent trading day (a -1.62% change compared to the prior day closing price) with a volume of 1.48K shares and market capitalization of 13.60M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 16 people. Aprea Therapeutics Inc. CEO is Oren Gilad.

The one-year performance of Aprea Therapeutics Inc. stock is -61.02%, while year-to-date (YTD) performance is -45.02%. APRE stock has a five-year performance of %. Its 52-week range is between 2.78 and 12, which gives APRE stock a 52-week price range ratio of 9.33%

Aprea Therapeutics Inc. currently has a PE ratio of -0.10, a price-to-book (PB) ratio of 0.91, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -245.51%, a ROC of -293.45% and a ROE of -294.79%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Aprea Therapeutics Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-1.08 for the next earnings report. Aprea Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Aprea Therapeutics Inc. is Strong Buy (1), with a target price of $3, which is -17.58% compared to the current price. The earnings rating for Aprea Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aprea Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aprea Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 20.52, ATR14 : 0.26, CCI20 : -83.50, Chaikin Money Flow : -0.08, MACD : -0.12, Money Flow Index : 62.66, ROC : -7.50, RSI : 43.87, STOCH (14,3) : 18.03, STOCH RSI : 0.50, UO : 29.45, Williams %R : -81.97), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aprea Therapeutics Inc. in the last 12-months were: Seizinger Bernd (Buy at a value of $36 954)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).

CEO: Oren Gilad

Telephone: +1 617 463-9385

Address: 535 Boylston Street, Boston 02116, MA, US

Number of employees: 16

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

52%48%

Bearish Bullish

57%43%

Bearish Bullish

57%43%

 

TipRanks News for APRE

Fri, 06 Oct 2023 17:25 GMT Promising Outlook for Aprea Therapeutics: A Buy Rating Based on Upcoming Safety Data and Synthetic Lethal Targeting Potential

- TipRanks. All rights reserved.

Thu, 21 Sep 2023 11:47 GMT Aprea Therapeutics (APRE) Gets a Buy from Maxim Group

- TipRanks. All rights reserved.

News

Stocktwits